Ligand Q3 Royalties Up 51% to $70.3M, Raises 2026 Adjusted EPS Guidance
LGND sits 77% above its 52-week low of $175.89.
Summary
Ligand's third-quarter royalty revenue rose 51% to $70.3 million and the company raised 2026 adjusted EPS guidance to $9.50-$9.75, even as a non-cash investment markdown pushed GAAP results to a $28.5 million net loss.
Key Events · Earnings and Guidance · LGND
-
Royalty Revenue Jumps 51%
Third-quarter royalty revenue reached $70.3 million versus $46.6 million a year earlier, with royalties at 89% of total revenues and income, driven by the XOMA portfolio plus Filspari and Ohtuvayre.
-
Adjusted EPS Guidance Raised
Full-year 2026 adjusted diluted EPS guidance moves to approximately $9.50-$9.75 from $9.00-$9.50, while total revenue guidance of $270-$310 million and royalty revenue of $225-$250 million are reaffirmed.
-
GAAP Loss Is Non-Cash
The $28.5 million net loss ($1.43 per share) stems largely from a $35.7 million fair-value loss on equity-method and other investments and a $3.8 million short-term investment loss; adjusted net income was $57.5 million, or $2.67 per diluted share.
-
Capital Position and Next Milestone
Cash, cash equivalents and short-term investments totaled $447.4 million at September 30, 2026, with roughly $750 million of deployable capital including equity investments and credit availability; an investor day on December 8 will present an updated five-year outlook.
Analysis · LGND · Life Sciences
Royalty revenue jumped 51% year-over-year to $70.3 million, powered by the newly acquired XOMA portfolio plus Filspari and Ohtuvayre, and management lifted full-year adjusted EPS guidance to $9.50-$9.75 from $9.00-$9.50 while reaffirming $270-$310 million of total revenue. The GAAP headline is a $28.5 million net loss ($1.43 per share), but that swing is almost entirely non-cash: a $35.7 million mark-to-market loss on equity-method and other investments plus a $3.8 million loss on short-term investments, against a $117.3 million profit a year ago that had been flattered by $53.1 million of Pelthos divestiture income. Adjusted net income of $57.5 million ($2.67 per diluted share) was down 10% on the prior year, again mostly because of that prior-year Pelthos income. What matters here is the royalty engine, and it is accelerating.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGND was trading at $311.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $175.89 to $326.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.